B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $46

B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $40 to $46.